Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 147

recruiting
3 987
countries
28
conditions
2 109

1 824 trials match your criteria

Malignant melanoma

Not recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Stage II-IV Melanoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab

Factor VIII deficiency+3

Not recruiting

Study on the Safety and Effectiveness of SerpinPC for Patients with Severe Hemophilia A or B

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years

Prostate cancer recurrent

Not recruiting

Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide

Diabetic neuropathy

Not recruiting

Study on GSK3858279 for Adults with Chronic Diabetic Nerve Pain

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:GSK3858279

Hepatocellular carcinoma

Not recruiting

Study on the Safety and Effectiveness of MK-1308A, Pembrolizumab, and Lenvatinib for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib

Acute coronary syndrome

Not recruiting

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid

Hodgkin's disease

Not recruiting

Study Comparing MK-4280A (Favezelimab and Pembrolizumab) with Chemotherapy for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab

Colitis ulcerative

Not recruiting

Study on Ustekinumab for Children with Moderate to Severe Ulcerative Colitis

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Ustekinumab

Endometrial cancer

Not recruiting

Study of Pembrolizumab with Chemotherapy for High-Risk Endometrial Cancer Patients After Surgery

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel

Ovarian cancer recurrent

Not recruiting

Study of Pembrolizumab, Paclitaxel, and Bevacizumab for Patients with Platinum-Resistant Recurrent Ovarian Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel

Renal cell carcinoma

Not recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Advanced Non-Clear Cell Kidney Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib

Neoplasm

Not recruiting

Study of Olaparib and Pembrolizumab for Patients with Advanced Cancer with HRRm or HRD Mutations

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.